<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714944</url>
  </required_header>
  <id_info>
    <org_study_id>NL72483.068.20</org_study_id>
    <nct_id>NCT04714944</nct_id>
  </id_info>
  <brief_title>Fiber and Insulin Sensitivity</brief_title>
  <official_title>Gut Microbial Substrate Switch to Improve Metabolic Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on previous research of the investigators group, the investigators hypothesize that&#xD;
      slowly fermentable fibers with a high degree of polymerization that increase SCFA&#xD;
      specifically in the distal colon are expected to have higher potential for influencing host&#xD;
      metabolism and metabolic health by improving adipose tissue function, preventing lipid&#xD;
      overflow and hepatic as well as skeletal muscle fat accumulation thereby improving insulin&#xD;
      sensitivity.&#xD;
&#xD;
      The objective of this randomized clinical trial is to test, whether the a dietary fiber&#xD;
      product containing different physiological acting fibers reverses peripheral and hepatic&#xD;
      insulin resistance in overweight/obese insulin resistant participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral insulin sensitivity</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change of peripheral insulin sensitivity as assessed by a hyperinsulinaemic-euglycemic clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hepatic and adipose tissue insulin sensitivity</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change in hepatic and adipose tissue insulin sensitivity as assessed by a hyperinsulinaemic-euglycemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy expenditure (indirect calorimetry)</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change in energy expenditure as measured via ventilated hood system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substrate oxidation (indirect calorimetry)</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change in substrate oxidation as measured via ventilated hood system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal and circulating SCFA</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change in faecal and circulating SCFA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal microbiota composition and in vitro microbial activity testing</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change in faecal microbiota composition as assessed via 16s rRNA gene sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vitro microbial activity testing</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change in fin vitro microbial activity testing as assessed using an in vitro model of the human colon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating hormones such as insulin</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change in circulating hormones in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating metabolites such as glucose</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change in metabolites in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory markers such as TNF</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change in inflammatory markers in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change in body weight in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change in body compostion as assessed using DEXA scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver fat content</measure>
    <time_frame>Before and 12 week after the start of the intervention</time_frame>
    <description>The change in liver fat content as assessed by proton magnetic resonance spectrometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>isocaloric placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>whole fiber product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 g for 2 weeks, followed by 30 g for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Supplementation period 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whole fiber product</intervention_name>
    <description>Supplementation period 12 weeks</description>
    <arm_group_label>whole fiber product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Overweight/obese insulin resistant/prediabetic participants (age 45-70 y, BMI ≥ 28 kg/m2 &lt;&#xD;
        35 kg/m2)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Type 2 diabetes mellitus (defined as fasting plasma glucose ≥ 7.0 mmol/L and 2h&#xD;
             glucose ≥ 11.1 mmol/L)&#xD;
&#xD;
          -  Gastroenterological diseases or abdominal surgery;&#xD;
&#xD;
          -  Cardiovascular diseases, cancer, liver or kidney malfunction, disease with a life&#xD;
             expectancy shorter than 5 years;&#xD;
&#xD;
          -  Abuse of products; alcohol and drugs, excessive nicotine use defined as &gt;20 cigarettes&#xD;
             per day;&#xD;
&#xD;
          -  Plans to lose weight or following of a hypocaloric diet;&#xD;
&#xD;
          -  Regular supplementation of pre- or probiotic products, use of pre- or probiotics 3&#xD;
             months prior to the start of the study;&#xD;
&#xD;
          -  Intensive exercise training more than three hours a week;&#xD;
&#xD;
          -  Use of any medication that influences glucose or fat metabolism and inflammation (i.e.&#xD;
             NSAIDs);&#xD;
&#xD;
          -  Regular use of laxation products;&#xD;
&#xD;
          -  Use of antibiotics in the last three months (antibiotics use can alter substantially&#xD;
             the gut microbiota composition).&#xD;
&#xD;
          -  Follow a vegetarian diet.&#xD;
&#xD;
          -  Metal objects such as implants present in the body (e.g. electronic implants,&#xD;
             pacemakers, metal fragments in the eyes, skin or body)&#xD;
&#xD;
          -  The use of permanent make-up (eyeliners, eyebrows) or tattoos on the head, shoulders,&#xD;
             breast or neck&#xD;
&#xD;
          -  Claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emanuel Canfora, PhD</last_name>
    <phone>+31-43 38 81669</phone>
    <email>emanuel.canfora@maastrichtuniversity.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>5229ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuel Canfora, PhD</last_name>
      <phone>+31-43 38 81669</phone>
      <email>emanuel.canfora@maastrichtuniversity.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

